Kura Oncology (KURA) announced the appointment of Brian Powl as Chief Commercial Officer. Powl has more than two decades of experience in the pharmaceutical and biotechnology industry, including extensive global experience in hematologic malignancies. Most recently, he served as Chief Commercial Officer for Fate Therapeutics (FATE).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KURA:
